Astec Lifesciences Q1 FY27 loss narrows to Rs 18.7 cr, revenue dips 8%

Revenue DeclinePat NegativeEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

ASTEC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+2.8%Reaction day

₹633.00

prior close

₹659.95

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.1%+1.7% vs market

Pesticides & Agrochemicals peers, median of 27sector+0.0%+2.8% vs sector

On the reaction day the stock moved 1.7 pts more than Nifty Microcap 250 and 2.8 pts more than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.4

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+2.8+1.1+1.7+0.0+2.8

Next day

-1.3+2.4-3.7+1.0-2.3

-1.4+2.9-4.3+1.3-2.7

-2.1+4.2-6.3+0.4-2.5

-2.7+4.6-7.2+0.3-3.0

-2.4+4.6-7.0-1.1-1.3

-3.3+4.4-7.7-0.0-3.3

15d

-5.1+5.7-10.8-3.2-1.9

-11.2+6.6-17.8-3.1-8.1

+13.1+5.4+7.7-12.1+25.2

—————

UpDownMarket · Nifty Microcap 250Sector · Pesticides & Agrochemicals peers, median of 27Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Astec Lifesciences reported Q1 FY27 consolidated revenue of Rs 83.6 cr, down 8.3% YoY from Rs 91.1 cr. Loss after tax narrowed sharply to Rs 18.7 cr versus Rs 33 cr loss in Q1 FY26. Operating margin improved to minus 0.79% from minus 12.06% YoY. Debt-equity ratio improved to 0.99 from 2.96. Auditors BSR and Co gave an unmodified review opinion on both standalone and consolidated results. FY26 had a Rs 2.09 cr exceptional item for Labour Codes impact.

Likely market impact

Losses persist but narrowing losses, stronger margins and lower debt-equity ratio signal gradual recovery for shareholders.